This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-08. Anything still debated is marked as such rather than presented as settled.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Cherish the Light Years (2011–2012) === In April 2011, Matador Records released his second album, Cherish the Light Years. In July 2011, Cold Cave remixed "I Didn't See It Coming" by the band Belle and Sebastian. The song appeared on their 12-inch single "Come On Sister" released by Matador Records and Rough Trade Records. In April 2012, Cold Cave performed at the Solomon R. Guggenheim Museum between John Chamberlain sculptures as part of the museum's Divine Ricochet series. In October 2012, Cold Cave performed at the Getty Center.
== Resurgence == By the late 2010s, many observers, including The New York Times, pointed to Detroit's economic and cultural resurgence. This resurgence was primarily due to private and public investment revitalizing the city's social and economic dynamics. Detroit has achieved a renewed sense of interest through reinvestment and revamped social policies. It serves as a model for other areas to learn how to re-energize their urban centers. In 2024, the United States Census Bureau reported that Detroit experienced a slight population increase in its 2023 estimates, marking the city's first recorded growth since 1957. Evidence of Detroit's resurgence is most readily found in the Midtown Area and the Central Business District, which have attracted a number of high-profile investors. Most notably, Dan Gilbert has heavily invested in the acquisition and revitalization of a number of historic buildings in the Downtown area. A primary focus of private real estate investment has been to position Detroit's Central Business District as an attractive site for the investment of technology companies such as Amazon, Google, and Microsoft. Approaches to the private investment of Midtown, however, have prioritized re-establishing Midtown as the cultural and commercial center of the city. Midtown Cultural Connection's DIA Plaza Project, for instance, aims to unify the city's cultural district—which includes the Detroit Institute of Arts, Detroit Public Library, the Charles H.
== Factors that influence results == Apart from the semen quality itself, there are various methodological factors that may influence the results, giving rise to inter-method variation. Compared to samples obtained from masturbation, semen samples from collection condoms have higher total sperm counts, sperm motility, and percentage of sperm with normal morphology. For this reason, they are believed to give more accurate results when used for semen analysis. If the results from a man's first sample are subfertile, they must be verified with at least two more analyses. At least two to four weeks must be allowed between each analysis. Results for a single man may have a large amount of natural variation over time, meaning a single sample may not be representative of a man's average semen characteristics. In addition, sperm physiologist Joanna Ellington believes that the stress of producing an ejaculate sample for examination, often in an unfamiliar setting and without any lubrication (most lubricants are somewhat harmful to sperm), may explain why men's first samples often show poor results while later samples show normal results. A man may prefer to produce his sample at home rather than at the clinic. The site of semen collection does not affect the results of a semen analysis. If produced at home, the sample should be kept as close to body temperature as possible, as exposure to cold or warm conditions can affect sperm motility.
Light oils (turpentine): Oils lighter than water that rise to the top. Pitch or tar: The heavy, nearly solid residue left at the bottom. Heavy oils (creosote): These are the "oils heavier than water." This specific fraction is the medical or industrial creosote, valued for its preservative and antiseptic properties.
As of 2023, Thermos and THERMOS remain a registered trademark in some countries, including the United States, but the lowercase "thermos" was declared a genericized trademark by court action in the United States in 1963.
Sources: en.wikipedia.org
In March 2002, as part of Task Force K-Bar, ODAs from 3rd SFG took part in Operation Anaconda, at around midnight on March 2, Task Force Hammer (consisting of Special Forces A-teams Texas 14/ODA 594 and 450 Afghan Militia Fighters led by Commander Zia Lodin) left their base at Gardez to take part in the operation. They were to enter the Shahikot valley from the north, then they would assault through the villages of Serkhankheyl and Marzak, where intelligence indicated that the enemy was concentrated, and channel fleeing enemy into the Task Force Rakkasan blocking positions Several soldiers were injured when their truck overturned due to the poor condition of the road, they decided to use their headlights, even though they would lose the element of surprise. An AC-130 Gunship, callsign Grim 31, that was providing fire support and reconnaissance for the operation, spotted the convoy; and due to a problem with the aircraft's inertial navigation system the aircraft failed to identify the Column as friendly unit. Grim 31 engaged the convoy killing CWO Stanley Harriman and wounding two other Green Berets and Afghan militia.
=== Ears === Some people find whispering or breathing softly in the ear to be pleasurable and relaxing, as well as licking, biting, caressing and/or kissing it especially the area of and behind the earlobe.
This process is run thousands or millions of times. The number of times a single tree is visited during the course of the chain is an approximation of its posterior probability. Some of the most common algorithms used in MCMC methods include the Metropolis–Hastings algorithms, the Metropolis-Coupling MCMC (MC³) and the LOCAL algorithm of Larget and Simon.
==== Small interfering RNA (siRNA) ==== siRNAs are small RNA molecules that induce the sequence-specific degradation of other RNAs. siRNA treatment can function similar to traditional gene therapy by destroying the mRNA products of particular genes, and therefore preventing the expression of those genes. A 2012 study found that targeting TERC with an siRNA reduced telomerase activity by more than 50% and resulted in decreased viability of immortal cancer cells. Treatment with both the siRNA and radiation caused a greater reduction in tumor size in mice than treatment with radiation alone, suggesting that targeting telomerase could be a way to increase the efficacy of radiation in treating radiation-resistant tumors.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.